Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 49 clinical trials
featured
  • 575 views
  • 24 Aug, 2021
  • 11 locations
featured
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

refractory follicular lymphoma
idelalisib
lymphoid malignancy
  • 307 views
  • 23 Nov, 2020
  • 6 locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …

  • 1 views
  • 29 Jan, 2021
  • 54 locations
  • 0 views
  • 11 Sep, 2021
  • 26 locations
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic

follicular lymphoma
ejection fraction
ct scan
marginal zone lymphoma
refractory follicular lymphoma
  • 127 views
  • 16 Apr, 2021
  • 145 locations
Dose Optimization Study of Idelalisib in Follicular Lymphoma

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other

refractory follicular lymphoma
follicular lymphoma
lymphoid malignancy
cancer
ct scan
  • 0 views
  • 03 Sep, 2021
  • 186 locations
IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3K Inhibitor, in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

  • 0 views
  • 24 Jan, 2021
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

  • 572 views
  • 01 Jul, 2021
  • 3 locations
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.

  • 0 views
  • 24 Jan, 2021
  • 30 locations
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or refractory to either chemotherapy or radioimmunotherapy (RIT).

  • 0 views
  • 03 Feb, 2021
  • 1 location